X4 Pharmaceuticals Company

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

Last Funding Type: Post-IPO Equity
Total Funding: 119499999
Last Funding Date: 2021
Funding Status: IPO
Employee Number: 51-100
Estimated Revenue: Less than $1M
Technology: Data-driven Technologies
Investors Number: 12
Founded Date: 2014
Headquarters: Cambridge, Massachusetts, United States
Industry: Biotechnology, Clinical Trials, Health Care, Pharmaceutical, Therapeutics
Investor Type: IPO